Work

Supplementary Materials and Methods from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice

Year: 2023
Type: supplementary-materials
Abstract: Supplementary Materials and Methods from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4362547911
Cites:
Cited by:
Related to: 10